| For: | Höpfner M, Schuppan D, Scherübl H. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World J Gastroenterol 2008; 14(46): 7021-7032 [PMID: 19084910 DOI: 10.3748/wjg.14.7021] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i46/7021.htm |
| Number | Citing Articles |
| 1 |
Linhua Yang, Ming Zhan, Ruifeng Yang, Miaomiao Guo, Min He, Yixiang Gu, Yang Zhang, Zhilian Jia, Xiaohua Huang, Bingyu Li, Hui Wang, Ruimeng Yang, Yingbin Liu. TP53 mutation promotes sunitinib resistance in gallbladder cancer via the ARHGEF7-AS2/miR-326/AXL pathway. Acta Pharmaceutica Sinica B 2026; doi: 10.1016/j.apsb.2026.08.019
|
| 2 |
Joshua A. Roth, Josh J. Carlson. Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer. Journal of Gastrointestinal Cancer 2012; 43(2) doi: 10.1007/s12029-010-9242-0
|
| 3 |
Tobias Kiesslich, Christian Mayr, Julia Wachter, Doris Bach, Julia Fuereder, Andrej Wagner, Beate Alinger, Martin Pichler, Pietro Di Fazio, Matthias Ocker, Frieder Berr, Daniel Neureiter. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Molecular and Cellular Biochemistry 2014; 396(1-2) doi: 10.1007/s11010-014-2161-9
|
| 4 |
Usha Dutta. Gallbladder cancer: Can newer insights improve the outcome?. Journal of Gastroenterology and Hepatology 2012; 27(4) doi: 10.1111/j.1440-1746.2011.07048.x
|
| 5 |
Mai-Lan Ho, Christine M. Peterson, Vamsidhar R. Narra. Abdominal Imaging. 2011; doi: 10.1016/B978-1-4160-5449-8.00086-X
|
| 6 |
|
| 7 |
Sanjeev K. Maurya, Mallika Tewari, Raghvendra R. Mishra, Hari S. Shukla. Genetic abberations in gallbladder cancer. Surgical Oncology 2012; 21(1) doi: 10.1016/j.suronc.2010.09.003
|